Australia's most trusted
source of pharma news
Tuesday, 24 June 2025
Posted 23 June 2025 AM
The TGA has approved a short-acting, ultra-high selective beta-1 adrenoreceptor blocker called Rapiblyk sponsored by Phebra.
Administered via intravenous infusion, Rapiblyk is indicated in adults for supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.